Endo Axiom

Endo Axiom Pty Ltd is an Australian biopharmaceutical company established in February 2023 as a spin-off from the University of Sydney and the Sydney Local Health District. The company was co-founded by Dr. Nicholas Hunt, who serves as CEO, alongside Professor Victoria Cogger and Professor David Le Couteur AO, who are scientific and clinical advisors, respectively. The founding team's twenty years of research culminated in the company's creation, driven by a key development in 2018 involving a responsive polymer for targeted insulin delivery.

The firm focuses on developing nanotechnology-based platforms to address significant challenges in medicine, specifically for treating diabetes and autoimmune diseases. Its business model is centered on advancing biotechnology platforms for the oral delivery of drugs and biologics through to clinical validation. The company's funding includes a combined $5 million in seed and non-dilutive funding, with notable backing from Australian biotech incubator Proto Axiom. This financial support is crucial for the company's progression towards commercialization and for retaining its intellectual property within Australia.

Endo Axiom is advancing two primary programs. The first, EA-1, is an oral peptide delivery platform for a 'smart' insulin therapy. This product, delivered as a pill, uses nanoparticles to transport insulin directly to the liver, mimicking the body's natural process. This method aims to offer convenience over injections and reduce the risk of hypoglycemia by releasing insulin in response to high blood sugar levels. The second program, EA-2, is an inverse vaccine platform designed to induce immune tolerance for autoimmune diseases like type 1 diabetes, without suppressing the entire immune system. Both programs have shown strong preclinical results and are moving toward Phase 1 clinical trials in 2025, with GMP manufacturing underway in partnership with companies like Ab Initio Pharma.

Keywords: oral insulin, nanotechnology drug delivery, autoimmune disease treatment, type 1 diabetes, immune modulation, inverse vaccine, biotechnology platform, clinical trials, biopharmaceutical, nanoparticle formulation, smart insulin, peptide delivery, immune tolerance, metabolic therapies, pre-clinical research, GMP manufacturing, Sydney Local Health District, University of Sydney spin-off, Proto Axiom, drug development